[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-uncontrolled\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-uncontrolled":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100301647","improving-hypertension-control-in-china-and-argentina-with-a-mobile-app-based-telecare-system-100301647",false,"NCT03206814","Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System","CHARGE-APP","Inclusion Criteria:\n\n* Male and female subjects;\n* Age 18-80 years;\n* Either the patient or another person close to him\u002Fher should possess a smartphone compatible with the ESH CARE app and be capable of using it;\n* Uncontrolled (untreated or treated) hypertension, defined as office BP ≥140\u002F90 mmHg, and Ambulatory 24h ABP ≥130\u002F80 mmHg\n\nExclusion Criteria:\n\n* eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m2 (CKD-EPI creatinine equation 2009);\n* Severe uncontrolled hypertension (i.e. BP ≥200\u002F120 mmHg despite treatment);\n* Known secondary hypertension;\n* Orthostatic hypotension (SBP fall \\> 20 mmHg on standing);\n* Unstable clinical conditions or severe disease with short life expectation;\n* Known atrial fibrillation;\n* Hepatic disease as determined by either AST or ALT values \\> 2 times the upper limit of normal;\n* History of gastrointestinal surgery or disorders which could interfere with drug absorption\n* History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years;\n* History of clinically significant autoimmune disorders such as systemic lupus erythematosus;\n* History of drug or alcohol abuse within the last 5 years;\n* History of non-compliance to medical regimens and\u002For patients who are considered potentially unreliable;\n* Dementia (clinical diagnosis);\n* Inability or unwillingness to give free informed consent;\n* Inability to use even simple communication technologies;\n* Pregnancy or planned pregnancy during study period","ALL","18 Years","80 Years",{"count":20,"type":21},480,"ESTIMATED","INTERVENTIONAL",[24],"NA","The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in outcome, including control rate of office, home and ambulatory BP, cardiovascular and renal intermediate end points at one year, and changes in a number of blood pressure-related variables throughout the study.",[27,28],"Hypertension,Essential","Hypertension, Uncontrolled",[30,31,32,33],"Hypertension","Ambulatory Systolic Blood Pressure","Home Blood Pressure","ESH-CARE APP","RECRUITING","2025-02-26",{"date":37,"type":38},"2025-02-27","ACTUAL",{"date":40,"type":38},"2021-05-11",{"date":42,"type":21},"2025-12",{"name":44,"class":45},"Istituto Auxologico Italiano","OTHER",8,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100568079","phase-4-intraprocedural-feedback-optimized-renal-denervation-based-on-measurements-obtained-through-renal-artery-stimulation-a-randomized-controlled-trial-inform-100568079","NCT06676553","INtraprocedural Feedback-Optimized Renal Denervation Based on Measurements Obtained Through Renal Artery Stimulation: a Randomized Controlled Trial (INFORM)","INtraprocedural Feedback-Optimized Renal Denervation Based on Measurements Obtained Through Renal Artery Stimulation: a Randomized Controlled Proof-of-concept Trial to Assess Whether Renal Denervation Guided by Renal Artery Stimulation Outperforms Conventional Renal Denervation in 6-month Ambulatory Blood Pressure Reductions","INFORM","Inclusion Criteria:\n\n* Patients with hypertension and are willing to undergo renal denervation.\n* Patients are treated with antihypertensive medications, or with an office systolic blood pressure (SBP) \\>140 mm Hg or diastolic blood pressure (DBP) \\>90 mm Hg, and 24-hour SBP of \\>130 mmHg or DBP \\>80 mm Hg, irrespective of antihypertensive treatment.\n\nExclusion Criteria:\n\n* An unsuitable renal artery anatomy for renal denervation, assessed by computed tomographic angiography (main renal artery lumen diameter \\\u003C3 mm or a total length \\\u003C20 mm).\n* Secondary hypertension, including hyperaldosteronism, pheochromocytoma, and renal artery stenosis (\\>50% stenosis in one or both arteries).",{"count":56,"type":21},32,[58],"PHASE4","Our previous study (Huang HC, Pan HY, Wang TD, Circ Cardiovasc Interv 2023;16:e012779) demonstrated that when renal artery stimulation continues to trigger systolic blood pressure increases (\\>=20 mmHg increase compared to baseline) after the initial procedure, patients show poor blood pressure reduction 6 months following renal denervation. Based on this finding, we designed a proof-of-concept trial comparing two approaches: a guided strategy versus conventional renal denervation. In the guided strategy, we perform additional ablations of main and\u002For branch renal arteries if immediate post-procedure stimulation still elevates systolic blood pressure (\\>=20 mmHg increase compared to baseline). The conventional approach involves no repeat procedures. This trial aims to determine whether the guided strategy leads to better clinical outcomes, measured by 6-month ambulatory blood pressure changes, and to establish the value of using intraprocedural feedback to assess and guide renal denervation treatment.",[28,61,30],"Hypertension, Resistant",[30,63,64,65,66],"Renal denervation","Electric stimulation","Renal artery","Radiofrequency ablation","2024-11-04",{"date":69,"type":38},"2024-11-06",{"date":71,"type":38},"2024-10-14",{"date":73,"type":21},"2028-06-30",{"name":75,"class":45},"National Taiwan University Hospital",1]